WAVE Life Sciences to Present at the SunTrust Robinson Humphrey 2016 Orphan Drug Day Conference

February 16, 2016
PDF Version

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 16, 2016-- WAVE Life Sciences Ltd. (NASDAQ: WVE), a genetic medicine company focused on developing stereopure nucleic acid therapies to deliver new and exceptional treatment options for patients impacted by rare diseases, today announced that Paul Bolno, M.D., MBA, President and Chief Executive Officer, will present at the SunTrust Robinson Humphrey 2016 Orphan Drug Day on Tuesday, February 23, 2016 at the JW Marriott Essex House in New York, NY.

WAVE is advancing more than 20 programs for rare and other serious diseases and intends to launch six clinical programs by 2018, starting with two clinical programs in Huntington’s disease by the end of the year.

About WAVE Life Sciences

WAVE Life Sciences is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering new treatment options for patients. Given the versatility of its chemistry platform, WAVE’s pipeline is designed to span multiple oligonucleotide modalities including antisense, exon-skipping, and single-stranded RNAi. For more information, please visit www.wavelifesciences.com and follow us on Twitter and LinkedIn.

Source: WAVE Life Sciences Ltd.

Media Contact:
Feinstein Kean Healthcare
Liz Melone, 617-256-6622
liz.melone@fkhealth.com
or
Investor Contact:
Westwicke Partners
Chris Brinzey, 339-970-2843
chris.brinzey@westwicke.com